デフォルト表紙
市場調査レポート
商品コード
1426136

ACE阻害薬の世界市場、薬剤別、投与経路別、適応症別、エンドユーザー別、地域別、機会、予測、2017年~2031年

ACE Inhibitors Market Assessment, Drugs, By Route of Administration, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 228 Pages | 納期: 3~5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.74円
ACE阻害薬の世界市場、薬剤別、投与経路別、適応症別、エンドユーザー別、地域別、機会、予測、2017年~2031年
出版日: 2024年02月16日
発行: Market Xcel - Markets and Data
ページ情報: 英文 228 Pages
納期: 3~5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のACE阻害薬の市場規模は、2023年に71億6,000万米ドルになりました。同市場は、2031年には108億6,000万米ドルに達すると予測され、2024年から2031年の予測期間のCAGRは5.34%になるとみられています。世界のACE阻害薬市場は、高血圧症などの心血管障害の有病率の上昇により、費用対効果の高い医薬品への需要が高まっていることなど、いくつかの要因によって牽引されています。高血圧治療のための革新的な新製品の投入は、市場成長を促進する主な要因です。さらに、さまざまな心血管疾患の管理におけるACE阻害薬の利点に対する認識の高まり、薬剤製剤の進歩、ACE阻害薬の有効性と安全性プロファイルの強化を目的とした研究開発活動などの要因も、市場に影響を与えています。

ACE阻害薬は心臓病患者の死亡予防と健康増進に非常に有益です。主要市場参入企業による新薬の開拓と、ECGなどの定期検診に関する患者の意識の高まりが、世界のACE阻害薬市場の成長を促進しています。さらに、政府の取り組みにより、発展途上国や低開発国におけるスクリーニング技術や効率的な医薬品開発へのアクセスが改善され、これらの市場におけるACE阻害薬へのアクセスが増加すると期待されています。

世界の心血管疾患の増加により、ACE阻害薬の需要が急増しています。ACE阻害薬は、静脈や動脈を弛緩させて血圧を下げるという重要な役割を担っています。そのため、ACE阻害薬は生命を脅かす心臓疾患を予防する重要な薬剤として機能します。米国心臓協会によると、2020年には約1,910万人が心血管疾患により死亡しています。虚血性心疾患は世界全体で約2億4,410万人が罹患しています。ACE阻害薬は、血圧や冠動脈疾患をコントロールし、心不全や心臓発作を予防するのに非常に有効です。ACE阻害薬の利点と可能性に関する人々の意識が高まっているため、ACE阻害薬の需要は世界的に一貫して増加しています。

当レポートでは、世界のACE阻害薬市場について調査し、市場の概要とともに、薬剤別、投与経路別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のACE阻害薬市場の展望、2017年~2031年

  • 市場規模と予測
  • 薬剤別
  • 投与経路別
  • 適応症別
  • エンドユーザー別
  • 地域別
  • 企業別市場シェア(%)、2023年

第5章 世界のACE阻害薬市場の見通し、地域別、2017年~2031年

  • 北米
  • 欧州
  • 南米
  • アジア太平洋
  • 中東・アフリカ

第6章 市場マッピング、2023年

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸出入分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca Plc.
  • Sanofi Winthrop Industries
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Lupin Pharmaceutical, Inc.
  • Sun Pharmaceutical Industries Limited
  • Bayer AG
  • Cipla Limited
  • AbbVie Inc.
  • Bristol-Myers Squibb Pharmaceuticals Limited

第14章 戦略的提言

第15章 お問合せと免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 4. Global ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 6. Global ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global ACE Inhibitors Market Share (%), By Region, 2017-2031F
  • Figure 8. North America ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 11. North America ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12. North America ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 13. North America ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 15. United States ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 18. United States ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 19. United States ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 20. United States ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 24. Canada ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25. Canada ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 26. Canada ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 30. Mexico ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31. Mexico ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 32. Mexico ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 36. Europe ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Europe ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 38. Europe ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 43. Germany ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Germany ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 45. Germany ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 46. France ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 49. France ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50. France ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 51. France ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 55. Italy ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 56. Italy ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 57. Italy ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 61. United Kingdom ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 62. United Kingdom ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 63. United Kingdom ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 67. Russia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Russia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 69. Russia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 73. Netherlands ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Netherlands ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 75. Netherlands ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 79. Spain ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Spain ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 81. Spain ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 85. Turkey ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Turkey ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 87. Turkey ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 91. Poland ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92. Poland ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 93. Poland ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 97. South America ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 98. South America ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 99. South America ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 104. Brazil ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. Brazil ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 106. Brazil ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 110. Argentina ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111. Argentina ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 112. Argentina ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 116. Asia-Pacific ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117. Asia-Pacific ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 118. Asia-Pacific ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 120. India ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 123. India ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124. India ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 125. India ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 126. China ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 129. China ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. China ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 131. China ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 135. Japan ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Japan ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 137. Japan ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 141. Australia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 142. Australia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 143. Australia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 147. Vietnam ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148. Vietnam ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 149. Vietnam ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 153. South Korea ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154. South Korea ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 155. South Korea ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 159. Indonesia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 160. Indonesia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 161. Indonesia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 165. Philippines ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Philippines ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 167. Philippines ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 171. Middle East & Africa ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Middle East & Africa ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 173. Middle East & Africa ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 178. Saudi Arabia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. Saudi Arabia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 180. Saudi Arabia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 184. UAE ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185. UAE ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 186. UAE ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 190. South Africa ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 191. South Africa ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 192. South Africa ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Drugs Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10999

Global ACE inhibitors market size was valued at USD 7.16 billion in 2023 and is expected to reach USD 10.86 billion in 2031, with a CAGR of 5.34% for the forecast period between 2024 and 2031. The global ACE inhibitors market is driven by several factors, including the rising prevalence of cardiovascular disorders, such as hypertension, which has increased demand for cost-effective drugs. Introducing new innovative products for treating hypertension is a major factor driving the market growth. Additionally, the market is influenced by factors such as the growing awareness of the benefits of ACE inhibitors in managing various cardiovascular conditions, advancements in drug formulations, and research and development activities aimed at enhancing ACE inhibitors' efficacy and safety profiles.

ACE Inhibitors are highly beneficial in preventing death and promoting health in heart patients. The development of novel drugs by the key market players and rising awareness among patients regarding regular check-ups, such as ECG, are driving the growth of the global ACE inhibitors market. Moreover, governmental initiatives are expected to improve access to screening technologies and efficient drug developments in developing and under-developed countries, which will increase access to ACE inhibitors in these markets.

Increasing Prevalence of Cardiovascular Patients

There has been a surge in demand for ACE Inhibitors due to rising number of cardiovascular diseases worldwide. ACE Inhibitors plays a crucial role in relaxing the veins and arteries to lower the blood pressure. Due to it, the inhibitors act as an important drug in preventing life-threating heart condition. According to American Heart Association, around 19.1 million people died in 2020 due to cardiovascular diseases. Around 244.1 million people were affected by ischemic heart diseases globally. ACE inhibitors are highly efficient in controlling blood pressure and coronary artery diseases and prevents heart failures and heart attack. There is an increased awareness among the people regarding benefits and potential of ACE inhibitors, due to which, there has been a consistent increase in demand for ACE inhibitors globally.

ACE Inhibitors are Receiving Significant Investments from Stakeholders

With high prevalence of cardiovascular diseases, there is a high demand to invest in research and development in the medicines for management of heart diseases. ACE Inhibitors have the potential to control and prevent heart health outcomes such as strokes, ischaemic heart diseases. Due to it, pharmaceuticals companies are continuously investing and launching modern ACE inhibitors.

In February 2023, Travere Therapeutics, Inc. announced FDA approval for Filspari to reduce proteinuria in adults, who are affected by IgAN, which is a rare kidney disease. Filspari is an ACE inhibitor which has proved to be beneficial for the patients suffering from IgAN and have the potential to reduce proteinuria and further prevent kidney failure.

Government Initiatives

As the prevalence of chronic diseases is increasing globally, governments are consistently launching initiatives and policies to improve access to ACE inhibitors in developed and emerging countries. Government support for research and development in the pharmaceutical industry, including the development of ACE inhibitors, is a key factor in driving innovation and market growth. Additionally, regulatory approval process and healthcare policies can impact market dynamics and the availability of ACE inhibitors.

For instance, World Heart Vision 2030 was launched by the World Heart Federation to bring policies and programs to improve cardiovascular health and reduce cardiovascular conditions such as heart failure and heart attack. Several steps were taken under these initiatives, such as increasing awareness regarding therapeutical approaches towards heart health, research and development for efficient drug discoveries, and improved accessibility to heart care facilities.

Rapid Growth in Demand for Lisinopril Drugs

Among the drugs segment, Lisinopril holds a significant share in global ACE inhibitors market. Tremendous research and development activities and increased investments by key market players in the segment are leading to the huge demand for Lisinopril Drugs in the ACE inhibitors market. Moreover, its potential to control blood pressure by widening blood vessels is the main reason behind its increasing demand. Due to this, many key market players are including drugs in their product portfolio. In September 2023, Almatica Pharma LLC., a global leader in developing medicines for several therapy areas such as cardiovascular diseases, psychiatry, and pain management recently received FDA approval for Zestril (lisinopril), specially manufactured for managing hypertension. Supportive regulatory systems are enabling pharmaceutical companies to invest and launch drugs for these heart conditions.

North America Holds the Largest Share in the Market

North America holds the highest share of the global ACE inhibitors market. Robust healthcare infrastructure and advanced healthcare facilities are some of the factors that make North America a global leader in the healthcare market. Growing awareness about the importance and benefits of screening and early diagnosis in preventing heart related diseases is driving the demand for ACE inhibitors globally. Growing focus on preventive healthcare, along with increasing availability of healthcare professionals, further leads to growing usage of ACE inhibitors for reducing the probability of mortality due to cardiovascular disorders. With the growing prevalence of cardiovascular diseases in the USA, there is a huge demand for ACE Inhibitors in the region. For instance, according to CDC, the most common cause of death in the United States is heart disease, and over 805,000 Americans get a heart attack each year. Due to this, the demand for ACE inhibitors is expected to grow in North America.

Future Market Scenario

Global ACE inhibitors market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing elderly population, which is prone to cardiovascular and other chronic diseases. It has further led to increase in demand for ACE Inhibitors to provide treatment. Rising awareness regarding the screening programs, along with increased research and developments are also contributing to the market's growth. Additionally, the market is being influenced by the growing demand for cost-effective drugs and the development of combination therapies such as ACE Inhibitors and diuretics and ACE Inhibitors and angiotensin receptor blockers. Geographically, Asia-Pacific is expected to experience the fastest growth, driven by a sizable population base, rising urbanization, and an increase in the prevalence of cardiovascular diseases.

Key Players Landscape and Outlook

In the ACE inhibitors market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in propelling the global ACE inhibitors market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level.

In January 2023, AstraZeneca acquired CinCor Pharma, Inc., a biopharmaceutical company, working on novel treatments for hypertension as well as chronic kidney disease by developing medicines such as ACE inhibitors. The strategic acquisition will enable the company to enhance its portfolio for the management of cardiovascular diseases, which will further expand the company's global presence.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global ACE Inhibitors Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Drugs
    • 4.2.1. Lisinopril
    • 4.2.2. Ramipril
    • 4.2.3. Enalapril
    • 4.2.4. Benazepril
    • 4.2.5. Fosinopril
    • 4.2.6. Captopril
    • 4.2.7. Moexipril
    • 4.2.8. Others
  • 4.3. By Route of Administration
    • 4.3.1. Oral
    • 4.3.2. Injectable
  • 4.4. By Indication
    • 4.4.1. Heart Failure
    • 4.4.2. Hypertension
    • 4.4.3. Diabetes
    • 4.4.4. Heart Attack
    • 4.4.5. Chronic Kidney Disease
    • 4.4.6. Others
  • 4.5. By End-user
    • 4.5.1. Retail Pharmacy
    • 4.5.2. Hospital Pharmacy
    • 4.5.3. Online Pharmacy
    • 4.5.4. E-commerce Websites
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. South America
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global ACE Inhibitors Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Drugs
      • 5.1.2.1. Lisinopril
      • 5.1.2.2. Ramipril
      • 5.1.2.3. Enalapril
      • 5.1.2.4. Benazepril
      • 5.1.2.5. Fosinopril
      • 5.1.2.6. Captopril
      • 5.1.2.7. Moexipril
      • 5.1.2.8. Others
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Oral
      • 5.1.3.2. Injectable
    • 5.1.4. By Indication
      • 5.1.4.1. Heart Failure
      • 5.1.4.2. Hypertension
      • 5.1.4.3. Diabetes
      • 5.1.4.4. Heart Attack
      • 5.1.4.5. Chronic Kidney Disease
      • 5.1.4.6. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Retail Pharmacy
      • 5.1.5.2. Hospital Pharmacy
      • 5.1.5.3. Online Pharmacy
      • 5.1.5.4. E-commerce Websites
    • 5.1.6. United States*
      • 5.1.6.1. By Drugs
      • 5.1.6.1.1. Lisinopril
      • 5.1.6.1.2. Ramipril
      • 5.1.6.1.3. Enalapril
      • 5.1.6.1.4. Benazepril
      • 5.1.6.1.5. Fosinopril
      • 5.1.6.1.6. Captopril
      • 5.1.6.1.7. Moexipril
      • 5.1.6.1.8. Others
      • 5.1.6.2. By Route of Administration
      • 5.1.6.2.1. Oral
      • 5.1.6.2.2. Injectable
      • 5.1.6.3. By Indication
      • 5.1.6.3.1. Heart Failure
      • 5.1.6.3.2. Hypertension
      • 5.1.6.3.3. Diabetes
      • 5.1.6.3.4. Heart Attack
      • 5.1.6.3.5. Chronic Kidney Disease
      • 5.1.6.3.6. Others
      • 5.1.6.4. By End-user
      • 5.1.6.4.1. Retail Pharmacy
      • 5.1.6.4.2. Hospital Pharmacy
      • 5.1.6.4.3. Online Pharmacy
      • 5.1.6.4.4. E-commerce Websites
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drugs
  • 6.2. By Route of Administration
  • 6.3. By Indication
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Pfizer Inc.
  • 13.3. AstraZeneca Plc.
  • 13.4. Sanofi Winthrop Industries
  • 13.5. Boehringer Ingelheim International GmbH
  • 13.6. Merck & Co., Inc.
  • 13.7. Lupin Pharmaceutical, Inc.
  • 13.8. Sun Pharmaceutical Industries Limited
  • 13.9. Bayer AG
  • 13.10. Cipla Limited
  • 13.11. AbbVie Inc.
  • 13.12. Bristol-Myers Squibb Pharmaceuticals Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer